# Tomas Koch

> Tomas Koch is a seed investor at TK & Partners backing Energy, Medical and Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [TK & Partners](https://shizune.co/investors/profile/tk-partners)
- Total investments: 3
- Last investment: Apr 2026
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/tomaskoch/

Tomas Koch is a seed investor at TK & Partners focused on Energy and Medical. Tomas Koch is theFounder and Chairman at TK&Partners.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Energy | 1 | 33% |
| Medical | 1 | 33% |
| Health Care | 1 | 33% |
| Biotechnology | 1 | 33% |
| Machine Learning | 1 | 33% |

8 industries tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Singapore | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Acurion | Acurion develops AI-driven diagnostic solutions that extract actionable genomic biomarker insights from standard pathology images to inform oncology treatment decisions. The company’s core product, OncoGaze™, analyzes digitized tumor biopsy slides to identify clinically relevant molecular features such as homologous recombination deficiency thatguide therapy selection more rapidly than conventional genomic testing. Acurion’s platform integrates into existing clinical workflows to support earlier precision medicine decisions for cancer care and is being expanded to detect additional biomarkers across various tumor types. The company collaborates with research and clinical partners to advance applications of its machine learning technology in oncology and related areas. | $4.3M | Seed | Apr 02, 2026 |  |
| Acurion | Acurion develops AI-driven diagnostic solutions that extract actionable genomic biomarker insights from standard pathology images to inform oncology treatment decisions. The company’s core product, OncoGaze™, analyzes digitized tumor biopsy slides to identify clinically relevant molecular features such as homologous recombination deficiency thatguide therapy selection more rapidly than conventional genomic testing. Acurion’s platform integrates into existing clinical workflows to support earlier precision medicine decisions for cancer care and is being expanded to detect additional biomarkers across various tumor types. The company collaborates with research and clinical partners to advance applications of its machine learning technology in oncology and related areas. | $2.1M | Seed | Jan 02, 2026 |  |
| HYDGEN | HydGen offers clean hydrogen solutions for an environmentally conscious future. | $1.5M | Seed | Feb 13, 2025 |  |

3 of 3 investments shown.

## Co-investors
- [Asian Fund For Cancer Research](https://shizune.co/investors/profile/asian-fund-for-cancer-research) — VC Fund, 1 deal together
- [Bootstrap Venture Partners](https://shizune.co/investors/profile/bootstrap-venture-partners) — VC Fund, 1 deal together
- [Cloudberry Pioneer Investments](https://shizune.co/investors/profile/cloudberry-pioneer-investments) — VC Fund, 1 deal together
- [Mesa Verde Venture Partners](https://shizune.co/investors/profile/mesa-verde-venture-partners) — VC Fund, 1 deal together
- [National Foundation for Cancer Research](https://shizune.co/investors/profile/national-foundation-for-cancer-research) — VC Fund, 1 deal together
- [National University of Singapore](https://shizune.co/investors/profile/national-university-of-singapore) — VC Fund, 1 deal together

## About TK & Partners

VC Fund · Bangkok, Thailand

TK & Partners is a McKinsey venture capital firm.

1 contacts available at TK & Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Tomas Koch | Founder and Chairman | https://shizune.co/investors/profile/tomas-koch |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Tomas Koch invest in?

Tomas Koch invests primarily in Energy, Medical and Health Care startups, most often at Seed stage. Most of the 3 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Tomas Koch last invest?

The most recent investment recorded for Tomas Koch closed in Apr 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co